At what fibrosis-risk threshold (e.g., liver stiffness or noninvasive fibrosis score) do you shift from recommending abstinence to urgent initiation of medications for alcohol use disorder and structured addiction treatment in alcohol-associated liver disease, and do you adjust that threshold in younger adults where FIB-4 is less reliable?